Skip to main content

Table 2 Dynamic alteration of serum sodium levels in cirrhotic patients treated with tolvaptan or placebo

From: Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia

 

Tolvaptan (n = 169)

Placebo (n = 61)

 

0 day

4 days

7 days

3 months

6 months

0 day

4 days

7 days

3 months

6 months

Normal sodium, mmol/L (n)

138.15 ± 2.58

(100)

140.28 ± 3.07

(95)

139.83 ± 3.32*

(95)

136.88 ± 5.09*

(56)

136.97 ± 6.92*

(49)

138.60 ± 2.24

(32)

138.52 ± 2.39

(29)

138.23 ± 2.16

(24)

136.97 ± 4.18

(14)

133.18 ± 9.31

(11)

Mild hyponatremia, mmol/L (n)

132.98 ± 1.31

(44)

138.02 ± 3.11**

(44)

136.59 ± 3.51**

(41)

133.78 ± 4.13**

(33)

131.96 ± 5.29**

(23)

131.96 ± 1.44

(21)

131.34 ± 3.03

(13)

131.06 ± 4.65

(13)

129.45 ± 6.66

(11)

134.50 ± 6.20

(9)

Middle hyponatremis, mmol/L (n)

127.35 ± 1.17

(19)

131.50 ± 2.85**

(18)

132.29 ± 2.87**

(18)

132.24 ± 5.71**

(11)

129.81 ± 7.02**

(10)

127.94 ± 0.92

(7)

130.30 ± 3.82

(5)

129.20 ± 10.32

(3)

134.30

(2)

139.30

(2)

Severe hyponatremia, mmol/L (n)

120.87 ± 3.33

(6)

126.87 ± 7.05**

(6)

126.50 ± 6.61**

(5)

131.10 ± 6.15**

(3)

132.30

(2)

124.80

(1)

ND

ND

ND

ND

  1. Compared with 0 day, *P > 0.05, **P < 0.01